AU2019333310B8 - Salts and crystal forms of GABAA positive allosteric modulator - Google Patents

Salts and crystal forms of GABAA positive allosteric modulator Download PDF

Info

Publication number
AU2019333310B8
AU2019333310B8 AU2019333310A AU2019333310A AU2019333310B8 AU 2019333310 B8 AU2019333310 B8 AU 2019333310B8 AU 2019333310 A AU2019333310 A AU 2019333310A AU 2019333310 A AU2019333310 A AU 2019333310A AU 2019333310 B8 AU2019333310 B8 AU 2019333310B8
Authority
AU
Australia
Prior art keywords
compound
exhibits
xrpd
peaks
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019333310A
Other languages
English (en)
Other versions
AU2019333310B2 (en
AU2019333310A8 (en
AU2019333310A1 (en
Inventor
Gabriel Martinez Botella
Paul A. Laskar
Nelson B. Olivier
Kiran Reddy
Magnus Ronn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praxis Precision Medicines Inc
Original Assignee
Praxis Precision Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Precision Medicines Inc filed Critical Praxis Precision Medicines Inc
Publication of AU2019333310A1 publication Critical patent/AU2019333310A1/en
Publication of AU2019333310B2 publication Critical patent/AU2019333310B2/en
Application granted granted Critical
Publication of AU2019333310A8 publication Critical patent/AU2019333310A8/en
Publication of AU2019333310B8 publication Critical patent/AU2019333310B8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
AU2019333310A 2018-08-31 2019-08-30 Salts and crystal forms of GABAA positive allosteric modulator Active AU2019333310B8 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862725805P 2018-08-31 2018-08-31
US62/725,805 2018-08-31
US16/517,369 US10562930B1 (en) 2018-08-31 2019-07-19 Salts and crystal forms of GABAA positive allosteric modulator
US16/517,369 2019-07-19
PCT/US2019/049103 WO2020047434A1 (en) 2018-08-31 2019-08-30 Salts and crystal forms of gabaa positive allosteric modulator

Publications (4)

Publication Number Publication Date
AU2019333310A1 AU2019333310A1 (en) 2021-04-08
AU2019333310B2 AU2019333310B2 (en) 2024-11-21
AU2019333310A8 AU2019333310A8 (en) 2025-04-17
AU2019333310B8 true AU2019333310B8 (en) 2025-04-17

Family

ID=69528249

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019333310A Active AU2019333310B8 (en) 2018-08-31 2019-08-30 Salts and crystal forms of GABAA positive allosteric modulator

Country Status (12)

Country Link
US (4) US10562930B1 (enExample)
EP (2) EP3710465B1 (enExample)
JP (3) JP7199739B2 (enExample)
KR (1) KR102845326B1 (enExample)
AU (1) AU2019333310B8 (enExample)
BR (1) BR112021003727A2 (enExample)
CA (1) CA3111193A1 (enExample)
IL (1) IL281143B2 (enExample)
MA (1) MA50921A (enExample)
MX (1) MX2021002382A (enExample)
TW (2) TWI850138B (enExample)
WO (1) WO2020047434A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117024502A (zh) * 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
CA3123248A1 (en) * 2018-12-14 2020-06-18 Praxis Precision Medicines, Inc. Methods for the treatment of depression
EP4125921A1 (en) 2020-03-25 2023-02-08 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
WO2022006541A1 (en) * 2020-07-02 2022-01-06 Praxis Precision Medicines, Inc. Methods for the treatment of adjustment disorder
WO2022177718A1 (en) 2021-02-18 2022-08-25 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
JP2024506942A (ja) * 2021-02-18 2024-02-15 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態
US20240207366A1 (en) 2021-04-27 2024-06-27 Kyungpook National University Industry-Academic Cooperation Foundation Food composition and pharmaceutical composition for preventing or alleviating sarcopenia, containing low-molecular-weight collagen as active ingredient
WO2023159035A1 (en) 2022-02-16 2023-08-24 Sage Therapeutics, Inc. Neuroactive steroids for treatment of cns-related disorders
US20250170148A1 (en) * 2022-02-28 2025-05-29 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131392A1 (en) * 2005-06-09 2006-12-14 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0701444B1 (en) * 1993-05-24 2010-04-07 Purdue Pharma Ltd. Methods and compositions for inducing sleep
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
PL185523B1 (pl) 1995-06-06 2003-05-30 Cocensys Inc Neuroaktywne steroidy z grupy pochodnych androstanu i pregnanu oraz kompozycja farmaceutyczna
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
YU77701A (sh) * 1999-04-29 2005-07-19 Euro-Celtique S.A. 3-α-HIDROKSI-3Гџ-METOKSIMETIL-21-HETEROCIKLIČNO SUPSTITUISANI STEROIDI SA ANESTETIČKIM DEJSTVOM
WO2004072079A1 (en) 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
WO2005007600A2 (en) 2003-07-11 2005-01-27 Eisai Co., Ltd. Novel methods using aminobenzoic acid compounds
JP2007502257A (ja) 2003-08-14 2007-02-08 エフ．ホフマン−ラ　ロシュ　アーゲー γアミノ酪酸作動性モジュレーター
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060074059A1 (en) 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
CN101466364A (zh) 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US20090074677A1 (en) 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
US20140315992A1 (en) 2011-07-07 2014-10-23 The Children's Hospital Of Philadelphia Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism
BR112016001446A8 (pt) 2013-07-24 2018-01-23 Commissariat Energie Atomique composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CN117024502A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US10420773B2 (en) 2017-09-26 2019-09-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with etifoxine
US20190160078A1 (en) 2017-11-10 2019-05-30 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disorders
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
CA3123248A1 (en) 2018-12-14 2020-06-18 Praxis Precision Medicines, Inc. Methods for the treatment of depression
MX2021007142A (es) 2018-12-17 2021-08-11 Intra Cellular Therapies Inc Compuestos organicos.
US20220125803A1 (en) 2019-03-04 2022-04-28 Praxis Precision Medicines, Inc. Methods for the treatment of perimenopause and menopause
WO2020185710A1 (en) 2019-03-08 2020-09-17 Alairion, Inc. Method for treating sleep fragmentation disorders using neurosteroid positive allosteric modulators of the gabaa receptor
US20220265666A1 (en) 2019-08-02 2022-08-25 Praxis Precision Medicines, Inc. Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression
CN114727989A (zh) 2019-10-02 2022-07-08 普拉西斯精密医药公司 Gaba-a受体正变构调节剂与nmda拮抗剂、nmda负变构调节剂或nmda部分激动剂的组合
WO2021168106A1 (en) 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
WO2022006541A1 (en) 2020-07-02 2022-01-06 Praxis Precision Medicines, Inc. Methods for the treatment of adjustment disorder
US20230416300A1 (en) 2020-08-20 2023-12-28 Intra-Cellular Therapies, Inc. Organic compounds
JP2024506942A (ja) 2021-02-18 2024-02-15 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態
CN117715641A (zh) 2021-04-26 2024-03-15 普拉西斯精密医药公司 用神经活性类固醇进行治疗的方法
WO2023159094A2 (en) 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE
WO2023211856A1 (en) 2022-04-26 2023-11-02 Praxis Precision Medicines, Inc. Methods for the treatment of neurological disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131392A1 (en) * 2005-06-09 2006-12-14 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof

Also Published As

Publication number Publication date
IL281143B2 (en) 2025-04-01
AU2019333310B2 (en) 2024-11-21
US10562930B1 (en) 2020-02-18
US20240140985A1 (en) 2024-05-02
US20200255471A1 (en) 2020-08-13
MX2021002382A (es) 2021-08-11
EP3710465A1 (en) 2020-09-23
TWI823999B (zh) 2023-12-01
MA50921A (fr) 2020-09-23
JP2025020120A (ja) 2025-02-12
IL281143A (en) 2021-04-29
EP3710465A4 (en) 2020-09-23
TWI850138B (zh) 2024-07-21
AU2019333310A8 (en) 2025-04-17
EP4458357A3 (en) 2024-12-18
EP3710465B1 (en) 2024-08-14
JP2021504297A (ja) 2021-02-15
WO2020047434A1 (en) 2020-03-05
CA3111193A1 (en) 2020-03-05
KR20210054546A (ko) 2021-05-13
US20220024967A1 (en) 2022-01-27
US12404297B2 (en) 2025-09-02
BR112021003727A2 (pt) 2021-05-25
TW202024108A (zh) 2020-07-01
IL281143B1 (en) 2024-12-01
AU2019333310A1 (en) 2021-04-08
JP2023036708A (ja) 2023-03-14
JP7199739B2 (ja) 2023-01-06
TW202408461A (zh) 2024-03-01
KR102845326B1 (ko) 2025-08-12
EP4458357A2 (en) 2024-11-06
US20200071350A1 (en) 2020-03-05
CN113473991A (zh) 2021-10-01
US10927141B2 (en) 2021-02-23

Similar Documents

Publication Publication Date Title
AU2019333310B8 (en) Salts and crystal forms of GABAA positive allosteric modulator
US20200190119A1 (en) Solid state forms of ixazomib citrate
US11434226B2 (en) Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof
HK40118203A (en) Salts and crystal forms of gabaa positive allosteric modulator
CN113473991B (zh) Gabaa阳性别构调节剂的盐和结晶形式
HK40037178B (en) Salts and crystal forms of gabaa positive allosteric modulator
HK40037178A (en) Salts and crystal forms of gabaa positive allosteric modulator

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
TH Corrigenda

Free format text: IN VOL 58 , NO 46 , PAGE(S) 6740 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME PRAXIS PRECISION MEDICINES, INC., APPLICATION NO. 2019333310, UNDER INID (54) CORRECT THE TITLE TO READ SALTS AND CRYSTAL FORMS OF GABAA POSITIVE ALLOSTERIC MODULATOR

Free format text: IN VOL 35 , NO 14 , PAGE(S) 3250 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME PRAXIS PRECISION MEDICINES, INC., APPLICATION NO. 2019333310, UNDER INID (54) CORRECT THE TITLE TO READ SALTS AND CRYSTAL FORMS OF GABAA POSITIVE ALLOSTERIC MODULATOR